OncoStem Diagnostics
Bangalore, India· Est.
Cost‑effective AI‑driven breast cancer prognostic test for personalized therapy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Cost‑effective AI‑driven breast cancer prognostic test for personalized therapy.
Oncology
Technology Platform
AI‑driven biomarker analysis of FFPE tumor tissue using a proprietary algorithm to calculate a five‑year recurrence risk score for early‑stage breast cancer.
Opportunities
Expansion into additional cancer indications, partnerships with regional hospital networks, and leveraging AI algorithm licensing for broader market penetration.
Risk Factors
Regulatory approval across new markets, competition from established multi‑gene assays, and the need for robust reimbursement pathways.
Competitive Landscape
Competes with Oncotype DX, MammaPrint, and Prosigna; differentiates through lower cost, validation in South Asian populations, and faster turnaround times.